# A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

> **NCT06148636** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **David Bushnell** · enrollment: 24 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Tumor Grade 1
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumor of Pancreas

## Interventions

- **DRUG:** [212Pb] VMT-α-NET
- **DIAGNOSTIC_TEST:** [203Pb] VMT-α-NET SPECT/CT

## Key facts

- **NCT ID:** NCT06148636
- **Lead sponsor:** David Bushnell
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06148636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06148636, "A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06148636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*